ALPHA Pharnext SA

Pharnext to Showcase Pioneering PLEOTHERAPYâ„¢ R&D Platform at 6th Annual Drug Repositioning, Repurposing and Rescue Conference

PARIS--(BUSINESS WIRE)--

Regulatory News:

Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that Xavier Paoli, Chief Commercial Officer and Vice President of R&D Operations and Rodolphe Hajj, Ph.D., Chief Pharmacology Officer, will present at the 6th Annual Drug Repositioning, Repurposing and Rescue Conference in Chicago, USA on Tuesday, June 27, 2017.

Details are as follow:

Date

 

Time

 

Location

Tuesday, June 27, 2017   11.00am CDT   Radisson Blu Aqua Hotel, Chicago

Their presentation, “A New Drug Discovery Paradigm Pioneered by Pharnext: PLEOTHERAPY™,” will offer insights into the Company’s innovative R&D paradigm. The PLEOTHERAPY™ R&D platform is universally applicable to any disease or compound, regardless of development stage or lifecycle status. It allows the identification and development of synergistic combinations of repositioned drugs at new optimal lower doses, known as PLEODRUG™. The presentation will also be an opportunity for the speakers to introduce Pharnext’s business model and growth strategy for years to come.

In addition, Dr. Hajj will participate in an expert panel discussion titled, “New Technologies and Methods to Advance Systematic Repurposing” on Tuesday, June 27, at 12:55 pm CDT.

If you are interested in meeting Mr. Paoli or Dr. Hajj at the event, please send an email to [email protected].

About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, visit www.pharnext.com

EN
20/06/2017

Underlying

ALPHAPharnext SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharnext SA

Sean Conroy
  • Sean Conroy
ALPHA PHARNEXT SA

Pharnext - Termination of coverage

Edison Investment Research is terminating coverage on ABC Arbitrage (ABCA), paragon (PGN), Foresight Solar Fund (FSFL), Kendrion (KENDR), Lithium Power International (LPI), Triple Point Energy Transition (TENT), 4iG (4IG), e-therapeutics (ETX), Pharnext (ALPHA) and Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our web...

04/23/24 April 23, 2024 1 EN
Sean Conroy
  • Sean Conroy
ALPHA PHARNEXT SA

Pharnext - Potential licensing deals could add confidence

Pharnext announced that it is in the final stages of signing a licensing agreement for its lead asset PXT3003. Management indicated that the non-binding bids for the asset are c €400m, with roughly 10% of potential total deal value to be received upfront. It expects to receive the first binding offers on 29 September and plans to conclude the transaction by the end of October. As a reminder, PXT3003 targets a rare genetic peripheral nerve disorder and is in the Phase III PREMIER trial with preli...

09/25/23 September 25, 2023 1 EN
Sean Conroy
  • Sean Conroy
ALPHA PHARNEXT SA

Pharnext - Improving FY23 financial footing

Pharnext’s FY22 results covered an eventful period marked by efforts to bolster its financial position to see it through to top-line readouts of its potentially first-in-class Phase III asset, PXT3003. FY22 also saw Pharnext strengthen its ties with Neovacs (following a strategic €20.7m debt funding agreement in September 2022 and a €24m debt commitment in January 2023), culminating in a revised legal framework with Neovacs’s CEO Hugo Brugière at the helm. The FY22 operating costs were higher th...

05/22/23 May 22, 2023 1 EN
Sean Conroy
  • Sean Conroy
ALPHA PHARNEXT SA

Pharnext - Revised legal structure to offer operational stability

In a bid to increase operational oversight and financial stability, Pharnext has changed its legal framework, from a public limited company to a limited partnership with shares, following shareholder approval. Pharnext Développement, a joint-stock company controlled by Neovacs (with Hugo Brugière as chairman), will be the sole general partner with existing shareholders as limited partners. This follows the January 2022 commitment by Neovacs to provide liquidity support to Pharnext (up to €24m to...

03/06/23 March 6, 2023 1 EN
Sean Conroy
  • Sean Conroy
ALPHA PHARNEXT SA

Pharnext - Neovacs trust to manage Pharnext deal

As a follow-up to the c €20.7m Neovacs strategic investment in Pharnext, the French biotech has set up a management trust with Equitis Gestion, as trustee, to manage obligations, rights and activities with respect to the convertible debt. In this capacity, Equitis Gestion will be responsible for managing all securities issued by Pharnext (including warrants to purchase the bonds plus associated warrants to subscribe to common equity) as well as related obligation and exercise rights. As a remind...

11/01/22 November 1, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch